Center for Biosimilars
One provision of the Lower Health Care Costs Act that has garnered significantly less attention from the broader healthcare community has raised concerns among many biologics stakeholders.
Little-Known Provision of Senate Healthcare Bill Has Some Biosimilar Stakeholders Worried